myriad genetics glp-1 receptor agonist weight management diabetes treatments Nutritional Care for Adults With Obesity Treated With Glucagon-Like Peptide (GLP)-1 and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Agonists: A Review of Evidence, Gaps, and Clinical Implications Efficacy and Safety of Glucagon-Like

Introduction Significant reductions in cardiovascular events, all-cause mortality, and the advancement of kidney disease are demonstrated by important studies such as FLOW

As the number of diabetic patien...

2026 is the year in which the long-term themes, the true drivers of sustainable success for the burgeoning landscape of obesity treatment, prescription medicines and beyond, become apparent

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan

GLP-1RA medications are the first pharmacotherapy for obesity with demonstrable cardiovascular benefits and ASCVD risk reduction

Learn why GLP-1 drugs cannot rebuild metabolism, and how SCFAs & gut bacteria may support lasting balance